Infigratinib was the first selective FGFR TKI to demonstrate efficacy in early clinical trials and subsequently was approved for previously treated, advanced/metastatic CCA with an FGFR2 genetic aberration (56, 57). This evidence concerns the gene FGFR2 and cholangiocarcinoma.